{"gene":"GPER1","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2012,"finding":"GPER1/GPR30 is a Gs-coupled heptahelical transmembrane receptor that promotes specific binding of estrogens, stimulates adenylyl cyclase, and mediates Gβγ-subunit protein-dependent release of membrane-tethered heparan-bound EGF (HB-EGF), constituting its core non-genomic signaling mechanism.","method":"cDNA cloning, pharmacological agonist/antagonist studies, receptor knockdown, adenylyl cyclase assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — replicated across multiple labs with multiple orthogonal methods; foundational mechanistic review synthesizing original experimental work","pmids":["22495674"],"is_preprint":false},{"year":2017,"finding":"GPER1 increases ERK1/2 activity via two Gi/o-mediated mechanisms: a PDZ motif-dependent constitutive mechanism requiring AKAP5 interaction, and a PDZ-independent G-1-stimulated mechanism; the constitutive mechanism requires PI3K but not EGFR transactivation, and involves a protein phosphatase.","method":"PDZ motif deletion mutants, AKAP5 knockdown, pertussis toxin, wortmannin, AG1478, FK506, okadaic acid, pharmacological inhibitors in receptor-expressing cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal pharmacological and genetic dissection methods in a single study, rigorous mechanistic controls","pmids":["28450397"],"is_preprint":false},{"year":2022,"finding":"In overexpressing HEK293 cells, GPR30/GPER1 couples canonically to Gq-phospholipase C, activating PKC and ERK, and undergoes rapid receptor internalization upon agonist exposure; plasma membrane integration and functional responses are cell-line-dependent.","method":"Multiplex GPCR Ca2+ screen, Gq inhibitor YM-254890, PKC and ERK assays, fluorescent fusion protein localization in multiple cell lines","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — unbiased screen plus multiple orthogonal signaling assays, rigorous controls including Gq inhibitor","pmids":["36400433"],"is_preprint":false},{"year":2017,"finding":"GPER1 constitutively interacts via its C-terminal type I PDZ motif with SAP97 and AKAP5, which anchor the receptor in the plasma membrane and mediate an apparently constitutive, Gi/o-independent decrease in cAMP production.","method":"Co-immunoprecipitation, PDZ motif deletion, siRNA knockdown of SAP97 and AKAP5, cAMP assay, pertussis toxin","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding partner identification with functional validation by knockdown and pharmacology","pmids":["28450397"],"is_preprint":false},{"year":2019,"finding":"GPER1 activates PRKACA (protein kinase A catalytic subunit alpha), which phosphorylates MORC2 at threonine 582; phosphorylated MORC2 has reduced interaction with the CMA components HSPA8 and LAMP2A, protecting it from lysosomal degradation and thereby promoting breast cancer cell proliferation and antiestrogen resistance.","method":"Co-immunoprecipitation, phosphorylation mutant (T582A), siRNA knockdown, rescue experiments with WT vs. mutant MORC2","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including binding studies, mutagenesis, knockdown, and functional rescue","pmids":["32401166"],"is_preprint":false},{"year":2013,"finding":"GPER1 stimulation by estradiol promotes fibronectin (FN) matrix assembly via release of HB-EGF, recruits integrin α5β1 to fibrillar adhesions, forms integrin α5β1-Shc adaptor protein complexes, enhances focal adhesion and actin stress fiber formation, and enables FN-dependent anchorage-independent growth; mutation of Shc Y317F abolishes these effects.","method":"Co-immunoprecipitation, Shc Y317F phosphorylation mutant, haptotaxis assay, hanging drop anchorage-independent growth assay, pharmacological agonist/antagonist","journal":"Hormones & cancer","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis of key tyrosine plus multiple functional assays in breast cancer cells","pmids":["25096985"],"is_preprint":false},{"year":2015,"finding":"GPER1 activation by estradiol or G-1 rapidly induces BDNF release in hippocampal CA3 field, leading to transient Arc protein translation and GluA1-containing AMPA receptor internalization; subsequent mGluR1 activation triggers LTD involving ubiquitination and proteasome-mediated GluA1 degradation.","method":"Selective agonist/antagonist pharmacology, BDNF measurement, Arc and GluA1 immunoblotting, proteasome inhibition, LTD electrophysiology","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal assays (biochemical + electrophysiological) with pharmacological dissection","pmids":["26391661"],"is_preprint":false},{"year":2015,"finding":"GPER1 activation by estradiol or G-1 stimulates adenylyl cyclase/cAMP production, which activates ERK/MAPK signaling and upregulates Runx2 expression in osteoblasts to promote bone regeneration.","method":"cAMP measurement, selective GPER1 antagonist G15 blockade, MAPK inhibitors, Runx2 protein/gene expression, in vivo bone drill-hole model","journal":"The Journal of nutritional biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection with in vitro and in vivo validation, single lab","pmids":["26345541"],"is_preprint":false},{"year":2013,"finding":"GPER1 agonist G-1 induces vasorelaxation in rat aorta through endothelium-dependent, Src-mediated EGFR transactivation and downstream Akt signaling, independent of ERα/ERβ and PI3K or ERK pathways.","method":"Isolated rat aortic ring organ bath pharmacology with selective inhibitors (L-NAME, AG1478, DAPH, Src inhibitor, Akt inhibitor VIII, LY294002, PD98059, G15, MPP, ICI182780)","journal":"The Journal of pharmacy and pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — thorough pharmacological dissection with multiple pathway inhibitors, single lab","pmids":["24028616"],"is_preprint":false},{"year":2013,"finding":"GPER1 mediates vasoconstriction in isolated perfused rat kidney via signaling pathways involving ROCK, PKC, p38 MAPK, p42/44 MAPK, tyrosine kinase, EGFR kinase, and voltage-operated Ca2+ channels (VOCCs), but not JNK or PI3K.","method":"Isolated perfused rat kidney pharmacology with selective inhibitors (Y-27632, genistein, SB203580, PD98059, GF109203X, SP600125, LY294002, nifedipine, AG-1478, G15), endothelium removal, Western blot for GPER1 expression","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — comprehensive pharmacological dissection with orthogonal inhibitors, single lab","pmids":["23376418"],"is_preprint":false},{"year":2013,"finding":"GPER1 agonist G-1 regulates vascular smooth muscle cell Ca2+ handling by reducing spontaneous Ca2+ spike activity and blocking L-type voltage-sensitive Ca2+ channel-mediated Ca2+ influx, in a GPER1-dependent manner.","method":"Live Ca2+ imaging in A7r5 vascular smooth muscle cells, nifedipine comparison, G15 antagonist blockade, KCl-evoked Ca2+ measurement","journal":"Journal of vascular research","confidence":"Medium","confidence_rationale":"Tier 2 — live cell imaging with pharmacological controls, single lab","pmids":["24080531"],"is_preprint":false},{"year":2014,"finding":"GPER1 mediates estradiol-induced inhibition of aldosterone synthesis through protein kinase A (PKA) signaling; silencing GPER1 lowers aldosterone synthase expression, while G-1 mimics the stimulatory effect of estradiol when ERβ is blocked, and a PKA inhibitor abrogates the G-1 effect.","method":"GPER1 siRNA knockdown, ERβ siRNA knockdown, selective agonist G-1, antagonist G-15, PKA inhibitor, aldosterone synthase expression and aldosterone production measurement in HAC15 adrenocortical cells","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic silencing plus pharmacological dissection, multiple endpoints, single lab","pmids":["25167221"],"is_preprint":false},{"year":2014,"finding":"GPER-1 activation lowers testosterone production by 20-30% in isolated rat Leydig cells and human testicular tissue, via a direct effect on steroidogenesis independent of cell viability.","method":"Isolated rat Leydig cells, human testicular tissue, GPER-1 selective agonist G-1, radioimmunoassay for testosterone, ICI 182,780, MTS cell viability assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — functional pharmacological assay in primary cells and human tissue, single lab","pmids":["24736568"],"is_preprint":false},{"year":2015,"finding":"GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in S and G2/M phases; this effect is GPER1-dependent as confirmed by siRNA knockdown and is independent of ERK/MAPK activity.","method":"GPER1 siRNA knockdown, flow cytometry cell-cycle analysis, BrdU DNA synthesis assay, ERK inhibitor PD98059, multiple endothelial cell lines","journal":"Journal of vascular research","confidence":"Medium","confidence_rationale":"Tier 2 — receptor knockdown confirms receptor dependence, pathway inhibitor shows ERK independence, multiple cell lines","pmids":["21273787"],"is_preprint":false},{"year":2015,"finding":"GPER1 stimulation with GPER1 agonist G1 increased ERK activity in hippocampal slices; the GPER1 antagonist G15 blocked estradiol-mediated enhancement of synaptic transmission; G1 prior application occluded further estradiol-induced synaptic enhancement, and ERK inhibition blocked the response.","method":"Extracellular field potential recording in hippocampal slices from WT, ERαKO, and ERβKO mice; selective agonists G1, PPT, DPN; G15 antagonist; ERK inhibitor","journal":"Hippocampus","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO plus pharmacological occlusion experiments establish GPER1 as primary mediator","pmids":["25980457"],"is_preprint":false},{"year":2019,"finding":"Autocrine motility factor (AMF) physically binds to GPER1 and the formed complex translocates from the plasma membrane to the cytoplasm, activating PI3K/AKT signaling to promote endometrial cancer cell growth.","method":"Co-immunoprecipitation, immunofluorescence co-localization, yeast two-hybrid assay, iTRAQ proteomics, xenograft mouse model","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple binding assays (co-IP, Y2H, IF) with functional in vivo validation, single lab","pmids":["30836961"],"is_preprint":false},{"year":2021,"finding":"GPER1 activation during pregnancy suppresses type I interferon (IFN) signaling disproportionately in reproductive and fetal tissues; GPER1 inactivation in mice halted fetal development and promoted fetal demise specifically in the context of maternal inflammation.","method":"Genetic GPER1 knockout mice, maternal inflammation model, IFN signaling assays, fetal development assessment","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with well-defined physiological phenotype in high-impact journal","pmids":["33446553"],"is_preprint":false},{"year":2020,"finding":"GPER1 mediates ubiquitin-proteasome-dependent degradation of ERα by upregulating the Cullin3-based E3 ubiquitin ligase adaptor SPOP; SPOP depletion abrogates GPER1-induced ERα ubiquitination and degradation, and GPER1 activation suppresses ERα-mediated transcription without affecting ERα mRNA.","method":"Co-immunoprecipitation, ubiquitination assay, SPOP siRNA knockdown, ERα protein/mRNA measurement, selective GPER1 agonist G-1, in vitro and in vivo breast cancer models","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 2 — genetic depletion of downstream effector SPOP plus ubiquitination assay confirms mechanism, multiple endpoints","pmids":["33069770"],"is_preprint":false},{"year":2014,"finding":"GPER1 stimulation alters posttranslational modification of RGSz1, increasing the high-molecular-weight (SUMOylated and glycosylated) RGSz1 isoform localized in detergent-resistant membrane microdomains (DRM), thereby functionally uncoupling 5-HT1AR signaling by sequestering active Gαz.","method":"G-1 selective agonist, subcellular fractionation (DRM isolation), Western blot for RGSz1 isoforms, SUMOylation/glycosylation analysis, in vivo oxytocin and ACTH hormone response assays","journal":"Neuroendocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical fractionation with PTM characterization plus in vivo functional readout, single lab","pmids":["25402859"],"is_preprint":false},{"year":2017,"finding":"GPER1 mediates estradiol-induced angiogenesis in HUVECs by upregulating the glycolytic enzyme PFKFB3; GPER1 antagonist G-15 or GPER1 siRNA abolishes the PFKFB3 upregulation, and PFKFB3 inhibition blocks GPER1-mediated HUVEC migration.","method":"GPER1 siRNA knockdown, G-15 antagonist, PFKFB3 inhibitor (3PO), selective G-1 agonist, angiogenesis assays (migration, tube formation), PFKFB3 protein expression","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA knockdown and pharmacological inhibition confirm pathway, multiple functional assays, single lab","pmids":["28348059"],"is_preprint":false},{"year":2015,"finding":"GPER1 activation by estradiol or G-1 in ER-negative breast cancer cells (SKBR3, BT-20) activates ERK, AKT, and NF-κB, leading to increased IL-8 secretion; blockade or knockdown of GPER1 inhibits these pathways and attenuates cancer cell migration and invasion, with downstream CXCR1 involvement.","method":"GPER1 siRNA knockdown, specific pathway inhibitors, IL-8 ELISA, migration/invasion assays, NF-κB translocation assay","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — knockdown plus pharmacological pathway dissection, multiple endpoints, single lab","pmids":["23907016"],"is_preprint":false},{"year":2015,"finding":"GPER1 mediates E2-induced inhibition of ERK1/2 (constitutively activated in granulosa cell tumors) through non-genomic mechanisms, suppressing migration and invasion of metastatic GCT cells; RNA silencing and pharmacological inhibition of GPER1 abrogated this effect.","method":"GPER1 siRNA, pharmacological agonist/antagonist, ERK1/2 phosphorylation assay, migration and invasion assays in KGN and COV434 cells","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — RNA silencing plus pharmacology with functional assays, single lab","pmids":["25823895"],"is_preprint":false},{"year":2016,"finding":"GPER1 activation reduces BBB permeability after global cerebral ischemia by preserving tight junction proteins (occludin and claudin-5) and decreasing VEGF-A expression in hippocampal CA1.","method":"Intracerebroventricular G1 agonist injection in ovariectomized rats, IgG extravasation assay, Western blot for occludin, claudin-5, VEGF-A","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo model with specific protein endpoint measurements, single lab","pmids":["27311857"],"is_preprint":false},{"year":2016,"finding":"GPER1 mediates estrogen-induced neuroprotection against oxygen-glucose deprivation (OGD) in primary hippocampal neurons via PI3K/Akt-dependent Ask1 inhibition; GPER1 knockdown diminishes and GPER1 overexpression potentiates neuroprotection by membrane-impermeable E2-BSA.","method":"GPER1 siRNA knockdown, GPER1 overexpression, E2-BSA (membrane-impermeable estradiol), PI3K/Akt inhibitor LY294002, cell viability assay in primary neurons","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional genetic manipulation (KD and overexpression) with pathway inhibitor, single lab","pmids":["27113328"],"is_preprint":false},{"year":2014,"finding":"Insulin transactivates the GPER1 promoter and increases GPER1 mRNA and protein expression through a PRKCD/MAPK1/c-Fos/AP1 signaling pathway in leiomyosarcoma cells and cancer-associated fibroblasts; GPER1 upregulation by insulin in turn mediates cell migration through CTGF and potentiates estrogen-stimulated glucose uptake and cell cycle progression.","method":"GPER1 promoter-luciferase reporter assay, pharmacological inhibitors, gene-silencing experiments, migration assays, glucose uptake assay","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 — promoter assay with inhibitors and silencing, multiple functional endpoints, single lab","pmids":["25012984"],"is_preprint":false},{"year":2015,"finding":"GPER1 inhibition in breast cancer cells via siRNA knockdown suppresses GPER1-mediated IGFBP-1 induction; 4-OHT activates GPER1, which signals through CREB to induce extracellular IGFBP-1 accumulation, which in turn inhibits IGF-1/Akt signaling.","method":"GPER1 siRNA knockdown, conditioned medium transfer assay, IGFBP-1 neutralization, CREB pathway analysis, phospho-Akt measurement","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockdown plus neutralization of effector with downstream signaling assay, single lab","pmids":["26690777"],"is_preprint":false},{"year":2014,"finding":"GPER1 and ERα36 (36 kDa splice variant) physically interact, and in human monocytes, ligand-activated ERα36 directly interacts with NF-κB p65 subunit in the nucleus to inhibit LPS-induced IL-6; GPER1 acts as a co-regulator in this process as its inhibition blocks the estrogen effect on IL-6.","method":"Co-immunoprecipitation, GPER1 selective inhibitor, siRNA knockdown, NF-κB reporter assay, IL-6 ELISA in human primary monocytes","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP for physical interaction, functional knockdown, single lab","pmids":["26394816"],"is_preprint":false},{"year":2021,"finding":"In breast cancer cells, ERα36 and GPER1 physically interact (especially after LPS treatment), and GPER1 directly interacts with NF-κB; together ERα36 and GPER1 inhibit TLR4/NF-κB-mediated inflammation independently of ERα66.","method":"Co-immunoprecipitation, ERα36 overexpression, siRNA knockdown of ERα36 and GPER1, NF-κB reporter assay, cytokine (TNFα, IL-6) measurement","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple co-IP experiments confirming physical interactions with functional validation, single lab","pmids":["34299224"],"is_preprint":false},{"year":2018,"finding":"GPER1 deletion in salt-sensitive hypertensive rats by CRISPR/Cas9 reduced blood pressure and was associated with altered gut microbiota and short-chain fatty acids; microbiotal transplantation from Gper1+/+ hypertensive rats reversed the cardiovascular protection of Gper1 deletion, demonstrating that GPER1 promotes microbiota alterations contributing to cardiovascular pathology.","method":"Multiplexed guide RNA CRISPR/Cas9 genomic excision of Gper1, fecal microbiota transplantation, blood pressure measurement, vascular relaxation assay, short-chain fatty acid measurement","journal":"Hypertension (Dallas, Tex. : 1979)","confidence":"Medium","confidence_rationale":"Tier 2 — complete gene ablation with microbiota transplantation rescue experiment, multiple endpoints","pmids":["30354811"],"is_preprint":false},{"year":2014,"finding":"GPER1 and CerS4/CerS5 promoter activation by 17β-estradiol is mediated through AP-1 (c-Jun/c-Fos dimerization); promoter deletion and mutation constructs demonstrated this AP-1 dependence, and GPER1 co-transfection modulated ceramide synthase promoter activities.","method":"Luciferase reporter assay with promoter deletion and mutation constructs, GPER1 co-transfection, fulvestrant inhibition, MCF-7 and MDA-MB-231 cells","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mutagenesis identifying functional AP-1 elements with GPER1 co-expression, single lab","pmids":["25451689"],"is_preprint":false},{"year":2019,"finding":"GPER1 overexpression in MCF-7 breast cancer cells causes G1 cell cycle arrest, induces autophagy/mitophagy, reduces basal respiration and glycolysis; stable GPER1 overexpression reduces CerS4, CerS5, and CerS6 promoter activity with the CerS5 effect mediated by GSK-3β signaling.","method":"Stable GPER1 overexpression, cell cycle analysis, autophagy assays, Seahorse metabolic assay, luciferase promoter assay, GSK-3β signaling inhibition","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — overexpression model with multiple metabolic readouts and promoter assay, single lab","pmids":["31082617"],"is_preprint":false},{"year":2022,"finding":"In mucopolysaccharidosis (MPS) I cells, GPER1 forms anomalous aggregates that co-localize with glycosaminoglycans (GAGs); enzyme replacement therapy that degrades GAGs causes disappearance of the GPER1 aggregates, indicating that GAG accumulation drives GPER1 aggregation rather than altered protein expression.","method":"Transcriptomic analysis, immunofluorescence localization, enzyme replacement treatment, correlation with GAG levels in MPS I and MPS II patient-derived cells","journal":"European journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 3 — localization plus GAG degradation rescue experiment, single lab","pmids":["35537249"],"is_preprint":false},{"year":2016,"finding":"In embryonic hippocampal mHippoE-18 cells, endogenous GPER1 mediates 17β-estradiol-induced potentiation of forskolin-stimulated cAMP; however, GPER1-selective antagonists G15 and G36 paradoxically switch this to an inhibitory response, and aldosterone mimics the inhibitory coupling even without antagonists, demonstrating biased agonism/antagonism dependent on ligand identity.","method":"cAMP assay with selective GPER1 agonists (G1, tamoxifen, ICI182780) and antagonists (G15, G36), ERα/ERβ agonists (PPT, DPN) in an endogenously expressing hippocampal cell line","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — endogenously expressing cell line avoids overexpression artifacts; multiple ligand comparisons demonstrating biased coupling, single lab","pmids":["26998610"],"is_preprint":false},{"year":2020,"finding":"GPER1 knockdown in gastric cancer cells suppresses proliferation, migration, and invasion by inhibiting PI3K/AKT-mediated EMT; PI3K activator 740Y-P reverses the effects of GPER1 knockdown on EMT markers, placing GPER1 upstream of PI3K/AKT in this pathway.","method":"GPER1 siRNA knockdown, GPER1 overexpression, PI3K activator rescue, EMT marker Western blot, proliferation/migration/invasion assays","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional genetic manipulation plus pathway rescue experiment, single lab","pmids":["33425895"],"is_preprint":false},{"year":2022,"finding":"BPS (bisphenol S) induces Agrp mRNA expression in hypothalamic neurons through GPER1 signaling; GPER1 antagonist G15 prevents BPS-mediated Agrp upregulation independently of Atf3 and Klf4 induction.","method":"G15 pharmacological antagonism, BPS treatment of immortalized hypothalamic cell lines, RT-PCR for Agrp and multiple transcription factors","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological pathway dissection without receptor knockdown, single lab","pmids":["35569583"],"is_preprint":false},{"year":2023,"finding":"GPER1 activation by G-1 in macrophages reduces M1 and M2 macrophage polarization, downregulates immune pathway activation and inactivates MAPK pathways, thereby reducing tubular epithelial cell injury and fibroblast ECM production in co-culture; GPER1 deletion in male UUO mice accelerates renal fibrosis.","method":"GPER1 agonist G-1 in OVX and male UUO mouse models, Gper1 knockout mice, RNA-sequencing, immunoblotting for MAPK pathway, macrophage polarization assays, co-culture experiments","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO plus pharmacological activation with RNA-seq and functional co-culture assays, single lab","pmids":["38086848"],"is_preprint":false},{"year":2023,"finding":"GPER1 activation by G-1 in multiple myeloma cells triggers apoptosis and upregulates the miR-29b oncosuppressive network by blunting a miR-29b-Sp1 feedback loop; this reduces MM growth in xenograft models even in bortezomib-resistant cells.","method":"Selective GPER1 agonist G-1, miR-29b expression analysis, Sp1 pathway assessment, apoptosis assay, xenograft mouse models","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway identified with in vivo validation, single lab","pmids":["37759449"],"is_preprint":false},{"year":2023,"finding":"E2 enhances melatonin synthesis (AANAT expression) in human trophoblast cells through GPER1-PKA-CREB signaling pathway; pharmacological dissection established this specific receptor-signaling axis in placental hormone homeostasis.","method":"Primary human trophoblast cell culture, GPER1 agonist/antagonist pharmacology, PKA inhibitor, CREB pathway analysis, AANAT expression measurement","journal":"Journal of pineal research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection with multiple inhibitors in primary human trophoblast cells, single lab","pmids":["37746893"],"is_preprint":false},{"year":2013,"finding":"GPER1 mediates ROCK-2 upregulation in rat coronary vascular endothelial cells via EGFR transactivation and Gi/o protein signaling, as evidenced by inhibition with pertussis toxin (PTX), AG-1478, G-15 antagonist, and actinomycin-D; ERα and ERβ selective agonists had no effect on ROCK-2.","method":"Western blot for ROCK-2 and GPER1, pertussis toxin, AG-1478, G-15 antagonist, actinomycin-D, primary rat coronary vascular endothelial cells","journal":"Endocrine regulations","confidence":"Low","confidence_rationale":"Tier 3 — pharmacological approach in primary cells, no genetic validation, single lab","pmids":["23641788"],"is_preprint":false},{"year":2019,"finding":"GPER1 activation by G-1 protects retinal ganglion cells from NMDA-induced apoptosis via PI3K/Akt pathway; pharmacological PI3K/Akt inhibitor LY294002 counteracts G-1 protection, and antibody array shows decreased Bad, Caspase 3, Caspase 7, Smad2, P53, and TAK1 in G-1-treated retinae.","method":"NMDA and AOH mouse models, G-1 agonist, G-15 antagonist, tamoxifen (ERα/ERβ blocker), LY294002 (PI3K inhibitor), immunofluorescence, TUNEL, antibody array","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 — receptor specificity established by G15 vs. tamoxifen pharmacology plus pathway inhibitor, single lab","pmids":["31586450"],"is_preprint":false}],"current_model":"GPER1 (GPR30) is a seven-transmembrane G protein-coupled receptor that functions as a membrane estrogen receptor, binding 17β-estradiol to activate multiple intracellular signaling cascades: it couples to Gs to stimulate adenylyl cyclase/cAMP, to Gi/o to activate ERK1/2 (via a PDZ motif/AKAP5-dependent constitutive mechanism and a ligand-stimulated PDZ-independent mechanism), and in some cell contexts to Gq-phospholipase C; it also transactivates EGFR via Gβγ-dependent release of membrane-tethered HB-EGF, activates PI3K/Akt, ROCK, PKC, and MAPK pathways, regulates fibronectin matrix assembly through integrin α5β1-Shc complexes, and mediates non-genomic control of cellular functions including BDNF release, calcium handling, PFKFB3-dependent angiogenesis, ERα ubiquitin-proteasome degradation via SPOP/Cullin3, MORC2 stabilization via PRKACA phosphorylation, IFN signaling suppression during pregnancy, and serotonin receptor desensitization through RGSz1 posttranslational modification, with its subcellular localization (plasma membrane vs. endomembrane compartments) being cell-type-dependent and influencing downstream signaling outputs."},"narrative":{"teleology":[{"year":2012,"claim":"Establishing that GPER1 is a bona fide Gs-coupled receptor for estrogen resolved the question of whether non-genomic estrogen signaling operates through a dedicated GPCR rather than through nuclear ERs alone, defining its core mechanism as adenylyl cyclase stimulation and Gβγ-dependent HB-EGF release for EGFR transactivation.","evidence":"Convergent pharmacological, knockdown, and adenylyl cyclase assay studies synthesized from multiple labs","pmids":["22495674"],"confidence":"High","gaps":["Structural basis of estrogen binding to a GPCR fold not resolved","Relative contribution of Gs vs. other G proteins in native tissues unclear"]},{"year":2013,"claim":"Defining GPER1's vascular signaling repertoire revealed that the same receptor drives opposing vascular responses—vasorelaxation via Src/EGFR/Akt in aorta and vasoconstriction via ROCK/PKC/MAPK/VOCCs in kidney—establishing GPER1 as a context-dependent modulator of vascular tone and calcium handling.","evidence":"Pharmacological dissection with extensive inhibitor panels in isolated rat aortic rings, perfused kidney, and vascular smooth muscle Ca²⁺ imaging","pmids":["24028616","23376418","24080531"],"confidence":"Medium","gaps":["Molecular determinants of tissue-specific G protein coupling not identified","No genetic validation of receptor dependence in vascular models","Endogenous ligand concentrations in vascular beds not measured"]},{"year":2013,"claim":"Demonstration that GPER1 stimulation promotes fibronectin matrix assembly through HB-EGF/integrin α5β1/Shc signaling—with Shc Y317F phosphorylation mutant abolishing anchorage-independent growth—established GPER1 as a direct link between estrogen signaling and extracellular matrix remodeling in breast cancer.","evidence":"Co-immunoprecipitation, Shc Y317F mutant, haptotaxis, and anchorage-independent growth assays in breast cancer cells","pmids":["25096985"],"confidence":"High","gaps":["Whether integrin α5β1-Shc axis operates in non-cancer epithelial cells unknown","Direct Shc binding site on GPER1 signaling complex not mapped"]},{"year":2014,"claim":"Identification of GPER1's role in modulating serotonin receptor desensitization through posttranslational modification of RGSz1 and sequestration of Gαz in detergent-resistant membrane microdomains provided a molecular mechanism for estrogen-serotonin crosstalk relevant to neuroendocrine regulation.","evidence":"Subcellular fractionation, RGSz1 SUMOylation/glycosylation analysis, and in vivo oxytocin/ACTH response after G-1 administration","pmids":["25402859"],"confidence":"Medium","gaps":["Direct physical interaction between GPER1 and RGSz1 not demonstrated","Enzymatic machinery mediating RGSz1 SUMOylation downstream of GPER1 not identified"]},{"year":2014,"claim":"Showing that GPER1 mediates estradiol's effects on steroid hormone production—inhibiting aldosterone synthesis via PKA signaling and reducing testosterone in Leydig cells—expanded the receptor's role beyond classical signal transduction to endocrine homeostasis.","evidence":"GPER1 siRNA, selective agonist G-1, PKA inhibitor in HAC15 adrenocortical cells; G-1 treatment of isolated rat Leydig cells and human testicular tissue","pmids":["25167221","24736568"],"confidence":"Medium","gaps":["Steroidogenic enzyme targets directly regulated by GPER1-PKA axis not fully mapped","Physiological relevance under normal endogenous estrogen levels not established"]},{"year":2015,"claim":"Discovery that GPER1 activation in hippocampus triggers BDNF release, transient Arc translation, GluA1 AMPA receptor internalization and subsequent proteasomal degradation established a complete molecular cascade through which estrogen rapidly modulates synaptic plasticity.","evidence":"Pharmacological dissection combined with electrophysiological LTD recording and biochemical measurement of Arc, GluA1, and BDNF in hippocampal slices","pmids":["26391661","25980457"],"confidence":"High","gaps":["Whether GPER1 acts cell-autonomously in neurons vs. through glia not resolved","Structural mechanism of GPER1-BDNF release coupling unknown"]},{"year":2017,"claim":"Dissection of two distinct ERK1/2 activation modes—a constitutive PDZ/AKAP5/Gi/o-dependent pathway requiring PI3K and a ligand-stimulated PDZ-independent pathway—resolved how GPER1 maintains basal signaling tone while retaining stimulus-responsiveness, and identified SAP97 and AKAP5 as scaffold partners anchoring GPER1 at the plasma membrane.","evidence":"PDZ motif deletion mutants, AKAP5/SAP97 knockdown, pertussis toxin, pathway inhibitors in receptor-expressing cells","pmids":["28450397"],"confidence":"High","gaps":["Crystal or cryo-EM structure of GPER1-AKAP5 complex not available","Whether PDZ-dependent constitutive signaling occurs in all GPER1-expressing cell types unknown"]},{"year":2017,"claim":"Identification of PFKFB3 as the downstream effector through which GPER1 drives endothelial angiogenesis linked GPER1 signaling to glycolytic metabolic reprogramming in vascular biology.","evidence":"GPER1 siRNA and G-15 antagonist abolish PFKFB3 upregulation; PFKFB3 inhibitor blocks GPER1-mediated HUVEC migration and tube formation","pmids":["28348059"],"confidence":"Medium","gaps":["Transcription factor(s) mediating GPER1-dependent PFKFB3 upregulation not identified","In vivo angiogenesis validation in GPER1 knockout mice not performed"]},{"year":2019,"claim":"Demonstrating that GPER1 activates PRKACA to phosphorylate MORC2-T582, protecting it from chaperone-mediated autophagy and promoting antiestrogen resistance, revealed a direct mechanism linking GPER1 to chromatin regulator stability and therapy resistance in breast cancer.","evidence":"Co-immunoprecipitation, T582A phospho-mutant, siRNA knockdown, rescue with WT vs. mutant MORC2","pmids":["32401166"],"confidence":"High","gaps":["Whether MORC2 stabilization is a general GPER1 output or breast cancer-specific unknown","Upstream mechanism selecting MORC2 as PRKACA substrate in GPER1 context not defined"]},{"year":2020,"claim":"Establishing that GPER1 promotes ERα degradation through upregulation of the SPOP/Cullin3 E3 ubiquitin ligase adaptor provided a molecular mechanism for the functional antagonism between GPER1 and classical nuclear estrogen receptor signaling.","evidence":"SPOP siRNA abrogates GPER1-induced ERα ubiquitination and degradation; GPER1 agonist G-1 suppresses ERα-mediated transcription without affecting ERα mRNA","pmids":["33069770"],"confidence":"High","gaps":["Whether GPER1 directly regulates SPOP transcription or protein stability not distinguished","In vivo tissue-specific impact on ERα levels in GPER1 knockout not assessed"]},{"year":2021,"claim":"Genetic knockout studies established that GPER1 suppresses type I interferon signaling in reproductive and fetal tissues during pregnancy, and that loss of GPER1 leads to fetal demise during maternal inflammation—demonstrating an essential physiological role beyond cancer biology.","evidence":"GPER1 knockout mice, maternal inflammation model, IFN signaling assays, fetal development assessment","pmids":["33446553"],"confidence":"High","gaps":["Molecular mechanism by which GPER1 suppresses IFN signaling not defined","Cell types responsible for IFN suppression in reproductive tract not identified"]},{"year":2022,"claim":"Demonstrating canonical Gq-PLC coupling and rapid agonist-induced internalization in an unbiased multiplex screen, with cell-line-dependent plasma membrane integration, clarified that GPER1's G protein selectivity and subcellular localization are not fixed properties but vary by cellular context.","evidence":"Multiplex GPCR Ca²⁺ screen, Gq inhibitor YM-254890, PKC/ERK assays, fluorescent fusion protein localization across multiple cell lines","pmids":["36400433"],"confidence":"High","gaps":["Determinants of cell-type-specific G protein coupling preference not identified","Structural basis for Gq vs. Gs vs. Gi/o selectivity unknown"]},{"year":2023,"claim":"Expansion of GPER1's immunomodulatory role to macrophage polarization and renal fibrosis—where GPER1 activation suppresses M1/M2 polarization via MAPK inactivation and GPER1 deletion accelerates fibrosis—extended the receptor's physiological relevance to tissue repair and inflammation beyond pregnancy.","evidence":"GPER1 agonist and knockout mice in UUO renal fibrosis model, RNA-seq, macrophage polarization and co-culture assays","pmids":["38086848"],"confidence":"Medium","gaps":["Direct GPER1 signaling targets in macrophages upstream of MAPK inactivation not mapped","Whether anti-fibrotic effect is macrophage-autonomous or involves other cell types not resolved"]},{"year":null,"claim":"The structural basis for GPER1's estrogen binding within a GPCR fold, the molecular determinants governing cell-type-specific G protein coupling selectivity, and the relative physiological contributions of constitutive versus ligand-stimulated signaling in vivo remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of GPER1 with or without ligand","In vivo contribution of constitutive PDZ/AKAP5-mediated signaling to physiology unknown","Mechanism of biased agonism at GPER1 (e.g., aldosterone vs. estradiol) not structurally or biochemically defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,32]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[17,18,26,27]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,3,15]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,15,31]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,3,7,8,9,23,33]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[16,26,27,35]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,17]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[6,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[36,39]}],"complexes":[],"partners":["AKAP5","SAP97","SPOP","MORC2","ESR1","AMF","RELA"],"other_free_text":[]},"mechanistic_narrative":"GPER1 (GPR30) is a seven-transmembrane G protein-coupled receptor that functions as a membrane estrogen receptor, mediating rapid non-genomic responses to 17β-estradiol and synthetic ligands across diverse tissues including breast, brain, vasculature, and reproductive organs. It couples to multiple G protein families—Gs to stimulate adenylyl cyclase/cAMP, Gi/o to activate ERK1/2 via both constitutive PDZ/AKAP5-dependent and ligand-stimulated mechanisms, and Gq to engage phospholipase C/PKC—and transactivates EGFR through Gβγ-dependent release of membrane-tethered HB-EGF, converging on PI3K/Akt, MAPK, PKA/CREB, and NF-κB signaling cascades [PMID:22495674, PMID:28450397, PMID:36400433]. These signaling outputs mediate cell-type-specific functions including BDNF-dependent synaptic plasticity and AMPA receptor internalization in hippocampus, fibronectin matrix assembly via integrin α5β1-Shc complexes, PFKFB3-dependent angiogenesis, SPOP/Cullin3-mediated ERα proteasomal degradation, steroidogenesis regulation, and calcium channel modulation in vascular smooth muscle [PMID:26391661, PMID:25096985, PMID:28348059, PMID:33069770, PMID:24080531]. GPER1 activation during pregnancy suppresses type I interferon signaling in reproductive and fetal tissues, and genetic loss of GPER1 in mice causes fetal demise during maternal inflammation [PMID:33446553]."},"prefetch_data":{"uniprot":{"accession":"Q99527","full_name":"G-protein coupled estrogen receptor 1","aliases":["Chemoattractant receptor-like 2","Flow-induced endothelial G-protein coupled receptor 1","FEG-1","G protein-coupled estrogen receptor 1","G-protein coupled receptor 30","GPCR-Br","IL8-related receptor DRY12","Lymphocyte-derived G-protein coupled receptor","LYGPR","Membrane estrogen receptor","mER"],"length_aa":375,"mass_kda":42.2,"function":"G-protein coupled estrogen receptor that binds to 17-beta-estradiol (E2) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Stimulates cAMP production, calcium mobilization and tyrosine kinase Src inducing the release of heparin-bound epidermal growth factor (HB-EGF) and subsequent transactivation of the epidermal growth factor receptor (EGFR), activating downstream signaling pathways such as PI3K/Akt and ERK/MAPK. Mediates pleiotropic functions among others in the cardiovascular, endocrine, reproductive, immune and central nervous systems. Has a role in cardioprotection by reducing cardiac hypertrophy and perivascular fibrosis in a RAMP3-dependent manner. Regulates arterial blood pressure by stimulating vasodilation and reducing vascular smooth muscle and microvascular endothelial cell proliferation. Plays a role in blood glucose homeostasis contributing to the insulin secretion response by pancreatic beta cells. Triggers mitochondrial apoptosis during pachytene spermatocyte differentiation. Stimulates uterine epithelial cell proliferation. Enhances uterine contractility in response to oxytocin. Contributes to thymic atrophy by inducing apoptosis. Attenuates TNF-mediated endothelial expression of leukocyte adhesion molecules. Promotes neuritogenesis in developing hippocampal neurons. Plays a role in acute neuroprotection against NMDA-induced excitotoxic neuronal death. Increases firing activity and intracellular calcium oscillations in luteinizing hormone-releasing hormone (LHRH) neurons. Inhibits early osteoblast proliferation at growth plate during skeletal development. Inhibits mature adipocyte differentiation and lipid accumulation. Involved in the recruitment of beta-arrestin 2 ARRB2 at the plasma membrane in epithelial cells. Also functions as a receptor for aldosterone mediating rapid regulation of vascular contractibility through the PI3K/ERK signaling pathway. Involved in cancer progression regulation. Stimulates cancer-associated fibroblast (CAF) proliferation by a rapid genomic response through the EGFR/ERK transduction pathway. Associated with EGFR, may act as a transcription factor activating growth regulatory genes (c-fos, cyclin D1). Promotes integrin alpha-5/beta-1 and fibronectin (FN) matrix assembly in breast cancer cells","subcellular_location":"Nucleus; Cytoplasm; Cytoplasm, perinuclear region; Cytoplasm, cytoskeleton; Cell membrane; Basolateral cell membrane; Cytoplasmic vesicle membrane; Early endosome; Recycling endosome; Golgi apparatus membrane; Golgi apparatus, trans-Golgi network; Endoplasmic reticulum membrane; Cell projection, dendrite; Cell projection, dendritic spine membrane; Cell projection, axon; Postsynaptic density; Mitochondrion membrane","url":"https://www.uniprot.org/uniprotkb/Q99527/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GPER1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GPER1","total_profiled":1310},"omim":[{"mim_id":"620560","title":"CEBPA DIVERGENT TRANSCRIPT; CEBPA-DT","url":"https://www.omim.org/entry/620560"},{"mim_id":"601805","title":"G PROTEIN-COUPLED ESTROGEN RECEPTOR 1; GPER1","url":"https://www.omim.org/entry/601805"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoli","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"stomach 1","ntpm":40.9}],"url":"https://www.proteinatlas.org/search/GPER1"},"hgnc":{"alias_symbol":["FEG-1","GPCR-Br","LERGU","LERGU2","DRY12","LyGPR","CEPR"],"prev_symbol":["CMKRL2","GPR30","GPER"]},"alphafold":{"accession":"Q99527","domains":[{"cath_id":"1.20.1070.10","chopping":"54-336","consensus_level":"high","plddt":86.6645,"start":54,"end":336}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99527","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99527-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99527-F1-predicted_aligned_error_v6.png","plddt_mean":79.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GPER1","jax_strain_url":"https://www.jax.org/strain/search?query=GPER1"},"sequence":{"accession":"Q99527","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99527.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99527/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99527"}},"corpus_meta":[{"pmid":"22495674","id":"PMC_22495674","title":"Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology.","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22495674","citation_count":293,"is_preprint":false},{"pmid":"19734054","id":"PMC_19734054","title":"GPR30/GPER1: searching for a role in estrogen physiology.","date":"2009","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/19734054","citation_count":186,"is_preprint":false},{"pmid":"26394816","id":"PMC_26394816","title":"Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERα36 and GPR30/GPER1.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26394816","citation_count":148,"is_preprint":false},{"pmid":"28465157","id":"PMC_28465157","title":"GPER1/GPR30 in the brain: Crosstalk with classical estrogen receptors and implications for behavior.","date":"2017","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28465157","citation_count":89,"is_preprint":false},{"pmid":"23849542","id":"PMC_23849542","title":"GPER-1 acts as a tumor suppressor in ovarian cancer.","date":"2013","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/23849542","citation_count":86,"is_preprint":false},{"pmid":"25980457","id":"PMC_25980457","title":"Contribution of estrogen receptor subtypes, ERα, ERβ, and GPER1 in rapid estradiol-mediated enhancement of hippocampal synaptic transmission in mice.","date":"2015","source":"Hippocampus","url":"https://pubmed.ncbi.nlm.nih.gov/25980457","citation_count":81,"is_preprint":false},{"pmid":"21250980","id":"PMC_21250980","title":"G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling.","date":"2011","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21250980","citation_count":75,"is_preprint":false},{"pmid":"27392633","id":"PMC_27392633","title":"Emerging roles for the novel estrogen-sensing receptor GPER1 in the CNS.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27392633","citation_count":68,"is_preprint":false},{"pmid":"26391661","id":"PMC_26391661","title":"A novel form of synaptic plasticity in field CA3 of hippocampus requires GPER1 activation and BDNF release.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26391661","citation_count":60,"is_preprint":false},{"pmid":"21273787","id":"PMC_21273787","title":"The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle.","date":"2011","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21273787","citation_count":60,"is_preprint":false},{"pmid":"25167221","id":"PMC_25167221","title":"GPER-1 and estrogen receptor-β ligands modulate aldosterone synthesis.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25167221","citation_count":57,"is_preprint":false},{"pmid":"28348059","id":"PMC_28348059","title":"The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1.","date":"2017","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28348059","citation_count":56,"is_preprint":false},{"pmid":"32401166","id":"PMC_32401166","title":"Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32401166","citation_count":55,"is_preprint":false},{"pmid":"25236887","id":"PMC_25236887","title":"GPER1 (GPR30) knockout mice display reduced anxiety and altered stress response in a sex and paradigm dependent manner.","date":"2014","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25236887","citation_count":54,"is_preprint":false},{"pmid":"24736568","id":"PMC_24736568","title":"Activation of GPER-1 estradiol receptor downregulates production of testosterone in isolated rat Leydig cells and adult human testis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24736568","citation_count":54,"is_preprint":false},{"pmid":"27311857","id":"PMC_27311857","title":"Activation of G protein-coupled estrogen receptor 1 (GPER-1) ameliorates blood-brain barrier permeability after global cerebral ischemia in ovariectomized rats.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27311857","citation_count":54,"is_preprint":false},{"pmid":"30354811","id":"PMC_30354811","title":"Attenuation of Microbiotal Dysbiosis and Hypertension in a CRISPR/Cas9 Gene Ablation Rat Model of GPER1.","date":"2018","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/30354811","citation_count":51,"is_preprint":false},{"pmid":"33446553","id":"PMC_33446553","title":"GPER1 is required to protect fetal health from maternal inflammation.","date":"2021","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33446553","citation_count":50,"is_preprint":false},{"pmid":"22749492","id":"PMC_22749492","title":"Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease.","date":"2012","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22749492","citation_count":48,"is_preprint":false},{"pmid":"23483801","id":"PMC_23483801","title":"GPER1/GPR30 activation improves neuronal survival following global cerebral ischemia induced by cardiac arrest in mice.","date":"2012","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/23483801","citation_count":48,"is_preprint":false},{"pmid":"26345541","id":"PMC_26345541","title":"Prunetin signals via G-protein-coupled receptor, GPR30(GPER1): Stimulation of adenylyl cyclase and cAMP-mediated activation of MAPK signaling induces Runx2 expression in osteoblasts to promote bone regeneration.","date":"2015","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26345541","citation_count":47,"is_preprint":false},{"pmid":"26051538","id":"PMC_26051538","title":"GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease.","date":"2015","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/26051538","citation_count":46,"is_preprint":false},{"pmid":"28450397","id":"PMC_28450397","title":"G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28450397","citation_count":46,"is_preprint":false},{"pmid":"23688258","id":"PMC_23688258","title":"GPER-1 expression decreases during breast cancer tumorigenesis.","date":"2013","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23688258","citation_count":44,"is_preprint":false},{"pmid":"25451689","id":"PMC_25451689","title":"Ceramide synthases CerS4 and CerS5 are upregulated by 17β-estradiol and GPER1 via AP-1 in human breast cancer cells.","date":"2014","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25451689","citation_count":41,"is_preprint":false},{"pmid":"30478785","id":"PMC_30478785","title":"G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.","date":"2018","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/30478785","citation_count":40,"is_preprint":false},{"pmid":"33425895","id":"PMC_33425895","title":"GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33425895","citation_count":39,"is_preprint":false},{"pmid":"25012984","id":"PMC_25012984","title":"GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts.","date":"2014","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25012984","citation_count":38,"is_preprint":false},{"pmid":"33117280","id":"PMC_33117280","title":"Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33117280","citation_count":37,"is_preprint":false},{"pmid":"25031742","id":"PMC_25031742","title":"High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25031742","citation_count":35,"is_preprint":false},{"pmid":"23907016","id":"PMC_23907016","title":"17β-estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1.","date":"2013","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23907016","citation_count":35,"is_preprint":false},{"pmid":"21196169","id":"PMC_21196169","title":"Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21196169","citation_count":32,"is_preprint":false},{"pmid":"24188886","id":"PMC_24188886","title":"GPCR-mediated rapid, non-genomic actions of steroids: comparisons between DmDopEcR and GPER1 (GPR30).","date":"2013","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24188886","citation_count":32,"is_preprint":false},{"pmid":"26998610","id":"PMC_26998610","title":"Characterisation of Signalling by the Endogenous GPER1 (GPR30) Receptor in an Embryonic Mouse Hippocampal Cell Line (mHippoE-18).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26998610","citation_count":31,"is_preprint":false},{"pmid":"30195206","id":"PMC_30195206","title":"Low-concentration BPF induced cell biological responses by the ERα and GPER1-mediated signaling pathways in MCF-7 breast cancer cells.","date":"2018","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/30195206","citation_count":30,"is_preprint":false},{"pmid":"27113328","id":"PMC_27113328","title":"GPER1 mediates estrogen-induced neuroprotection against oxygen-glucose deprivation in the primary hippocampal neurons.","date":"2016","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27113328","citation_count":30,"is_preprint":false},{"pmid":"31635400","id":"PMC_31635400","title":"A Novel Mechanism of S-equol Action in Neurons and Astrocytes: The Possible Involvement of GPR30/GPER1.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31635400","citation_count":29,"is_preprint":false},{"pmid":"29964007","id":"PMC_29964007","title":"Is the membrane estrogen receptor, GPER1, a promiscuous receptor that modulates nuclear estrogen receptor-mediated functions in the brain?","date":"2018","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/29964007","citation_count":29,"is_preprint":false},{"pmid":"28263910","id":"PMC_28263910","title":"Depressive-like effect of prenatal exposure to DDT involves global DNA hypomethylation and impairment of GPER1/ESR1 protein levels but not ESR2 and AHR/ARNT signaling.","date":"2017","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28263910","citation_count":28,"is_preprint":false},{"pmid":"30836961","id":"PMC_30836961","title":"Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1.","date":"2019","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/30836961","citation_count":26,"is_preprint":false},{"pmid":"30267584","id":"PMC_30267584","title":"Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR-103/GPER1 axis.","date":"2018","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/30267584","citation_count":25,"is_preprint":false},{"pmid":"23376418","id":"PMC_23376418","title":"Vasoconstriction induced by G1, a G-protein-coupled oestrogen receptor1 (GPER-1) agonist, in the isolated perfused rat kidney.","date":"2013","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23376418","citation_count":25,"is_preprint":false},{"pmid":"35520492","id":"PMC_35520492","title":"Sequential ligand- and structure-based virtual screening approach for the identification of potential G protein-coupled estrogen receptor-1 (GPER-1) modulators.","date":"2019","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35520492","citation_count":25,"is_preprint":false},{"pmid":"30092317","id":"PMC_30092317","title":"Role of estrogens in fish immunity with special emphasis on GPER1.","date":"2018","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30092317","citation_count":24,"is_preprint":false},{"pmid":"25823895","id":"PMC_25823895","title":"17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1.","date":"2015","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25823895","citation_count":24,"is_preprint":false},{"pmid":"26772481","id":"PMC_26772481","title":"Understanding the molecular basis of agonist/antagonist mechanism of GPER1/GPR30 through structural and energetic analyses.","date":"2016","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26772481","citation_count":24,"is_preprint":false},{"pmid":"33281743","id":"PMC_33281743","title":"G Protein-Coupled Estrogen Receptor, GPER1, Offers a Novel Target for the Treatment of Digestive Diseases.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33281743","citation_count":23,"is_preprint":false},{"pmid":"31586450","id":"PMC_31586450","title":"The neuroprotective effects of novel estrogen receptor GPER1 in mouse retinal ganglion cell degeneration.","date":"2019","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/31586450","citation_count":23,"is_preprint":false},{"pmid":"24080531","id":"PMC_24080531","title":"The G protein-coupled estrogen receptor 1 (GPER1/GPR30) agonist G-1 regulates vascular smooth muscle cell Ca²⁺ handling.","date":"2013","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/24080531","citation_count":23,"is_preprint":false},{"pmid":"24718680","id":"PMC_24718680","title":"Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway.","date":"2014","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24718680","citation_count":22,"is_preprint":false},{"pmid":"30405852","id":"PMC_30405852","title":"Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1.","date":"2018","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30405852","citation_count":22,"is_preprint":false},{"pmid":"24028616","id":"PMC_24028616","title":"GPER-1 agonist G1 induces vasorelaxation through activation of epidermal growth factor receptor-dependent signalling pathway.","date":"2013","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24028616","citation_count":22,"is_preprint":false},{"pmid":"27512921","id":"PMC_27512921","title":"Serum levels of G protein-coupled estrogen receptor 1 (GPER1) in drug-naive patients with generalized anxiety disorder.","date":"2016","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/27512921","citation_count":22,"is_preprint":false},{"pmid":"28286086","id":"PMC_28286086","title":"Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28286086","citation_count":21,"is_preprint":false},{"pmid":"25096985","id":"PMC_25096985","title":"The G protein-coupled estrogen receptor-1, GPER-1, promotes fibrillogenesis via a Shc-dependent pathway resulting in anchorage-independent growth.","date":"2014","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25096985","citation_count":21,"is_preprint":false},{"pmid":"32813115","id":"PMC_32813115","title":"G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: impact of GPER-1 mRNA on survival.","date":"2020","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32813115","citation_count":21,"is_preprint":false},{"pmid":"26981789","id":"PMC_26981789","title":"The protective role of G protein-coupled estrogen receptor 1 (GPER-1) on methotrexate-induced nephrotoxicity in human renal epithelium cells.","date":"2016","source":"Renal failure","url":"https://pubmed.ncbi.nlm.nih.gov/26981789","citation_count":21,"is_preprint":false},{"pmid":"34248622","id":"PMC_34248622","title":"Bazi Bushen Capsule Alleviates Post-Menopausal Atherosclerosis via GPER1-Dependent Anti-Inflammatory and Anti-Apoptotic Effects.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34248622","citation_count":20,"is_preprint":false},{"pmid":"34299224","id":"PMC_34299224","title":"ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299224","citation_count":20,"is_preprint":false},{"pmid":"26722308","id":"PMC_26722308","title":"Oxidative/antioxidative enzyme-mediated antiproliferative and proapoptotic effects of the GPER1 agonist G-1 on lung cancer cells.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26722308","citation_count":20,"is_preprint":false},{"pmid":"26093261","id":"PMC_26093261","title":"Activation of G protein-coupled estrogen receptor 1 (GPER-1) decreases fluid intake in female rats.","date":"2015","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/26093261","citation_count":20,"is_preprint":false},{"pmid":"34714484","id":"PMC_34714484","title":"Saikosaponin-d alleviates hepatic fibrosis through regulating GPER1/autophagy signaling.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34714484","citation_count":19,"is_preprint":false},{"pmid":"31900584","id":"PMC_31900584","title":"GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.","date":"2020","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/31900584","citation_count":19,"is_preprint":false},{"pmid":"31082617","id":"PMC_31082617","title":"GPER1 influences cellular homeostasis and cytostatic drug resistance via influencing long chain ceramide synthesis in breast cancer cells.","date":"2019","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31082617","citation_count":17,"is_preprint":false},{"pmid":"33193108","id":"PMC_33193108","title":"Does GPER1 Play a Role in Sexual Dimorphism?","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33193108","citation_count":17,"is_preprint":false},{"pmid":"32077170","id":"PMC_32077170","title":"The G protein-coupled oestrogen receptor, GPER1, mediates direct anti-inflammatory effects of oestrogens in human cholinergic neurones from the nucleus basalis of Meynert.","date":"2020","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32077170","citation_count":16,"is_preprint":false},{"pmid":"29807036","id":"PMC_29807036","title":"Selective activation of estrogen receptors, ERα and GPER-1, rapidly decreases food intake in female rats.","date":"2018","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/29807036","citation_count":16,"is_preprint":false},{"pmid":"31040364","id":"PMC_31040364","title":"Targeting GPER1 to suppress autophagy as a male-specific therapeutic strategy for iron-induced striatal injury.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31040364","citation_count":16,"is_preprint":false},{"pmid":"33069770","id":"PMC_33069770","title":"The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33069770","citation_count":16,"is_preprint":false},{"pmid":"32302699","id":"PMC_32302699","title":"The novel estrogen receptor GPER1 decreases epilepsy severity and susceptivity in the hippocampus after status epilepticus.","date":"2020","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/32302699","citation_count":15,"is_preprint":false},{"pmid":"25402859","id":"PMC_25402859","title":"GPER1 stimulation alters posttranslational modification of RGSz1 and induces desensitization of 5-HT1A receptor signaling in the rat hypothalamus.","date":"2014","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25402859","citation_count":15,"is_preprint":false},{"pmid":"31698960","id":"PMC_31698960","title":"Environmental polycyclic aromatic hydrocarbons mixture, in human blood levels, decreased oestradiol secretion by granulosa cells via ESR1 and GPER1 but not ESR2 receptor.","date":"2019","source":"Human & experimental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/31698960","citation_count":15,"is_preprint":false},{"pmid":"26690777","id":"PMC_26690777","title":"GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26690777","citation_count":14,"is_preprint":false},{"pmid":"36288854","id":"PMC_36288854","title":"Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERβ Agonists.","date":"2022","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36288854","citation_count":14,"is_preprint":false},{"pmid":"35803362","id":"PMC_35803362","title":"Bisphenol F blocks Leydig cell maturation and steroidogenesis in pubertal male rats through suppressing androgen receptor signaling and activating G-protein coupled estrogen receptor 1 (GPER1) signaling.","date":"2022","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/35803362","citation_count":14,"is_preprint":false},{"pmid":"33193095","id":"PMC_33193095","title":"Chronic GPER1 Activation Protects Against Oxidative Stress-Induced Cardiomyoblast Death via Preservation of Mitochondrial Integrity and Deactivation of Mammalian Sterile-20-Like Kinase/Yes-Associated Protein Pathway.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33193095","citation_count":14,"is_preprint":false},{"pmid":"33014211","id":"PMC_33014211","title":"MiR-155-Mediated Deregulation of GPER1 Plays an Important Role in the Gender Differences Related to Inflammatory Bowel Disease.","date":"2020","source":"The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale","url":"https://pubmed.ncbi.nlm.nih.gov/33014211","citation_count":13,"is_preprint":false},{"pmid":"37093686","id":"PMC_37093686","title":"Knockdown of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances Tumor-supportive Properties in Cervical Carcinoma Cells.","date":"2023","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/37093686","citation_count":13,"is_preprint":false},{"pmid":"38086848","id":"PMC_38086848","title":"Activation of GPER1 in macrophages ameliorates UUO-induced renal fibrosis.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38086848","citation_count":12,"is_preprint":false},{"pmid":"37746893","id":"PMC_37746893","title":"Orchestrated feedback regulation between melatonin and sex hormones involving GPER1-PKA-CREB signaling in the placenta.","date":"2023","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/37746893","citation_count":12,"is_preprint":false},{"pmid":"35537249","id":"PMC_35537249","title":"Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells.","date":"2022","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35537249","citation_count":12,"is_preprint":false},{"pmid":"23641788","id":"PMC_23641788","title":"G protein-coupled estrogen receptor1 (GPER1) may mediate Rho-kinase (ROCK-2) up-regulation in coronary endothelial cells.","date":"2013","source":"Endocrine regulations","url":"https://pubmed.ncbi.nlm.nih.gov/23641788","citation_count":11,"is_preprint":false},{"pmid":"28688795","id":"PMC_28688795","title":"GPER1 in sand rat epididymis: Effects of seasonal variations, castration and efferent ducts ligation.","date":"2017","source":"Animal reproduction science","url":"https://pubmed.ncbi.nlm.nih.gov/28688795","citation_count":11,"is_preprint":false},{"pmid":"28374135","id":"PMC_28374135","title":"Oxabicycloheptene Sulfonate Protects Against β-Amyloid-induced Toxicity by Activation of PI3K/Akt and ERK Signaling Pathways Via GPER1 in C6 Cells.","date":"2017","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/28374135","citation_count":11,"is_preprint":false},{"pmid":"29618927","id":"PMC_29618927","title":"Serum levels of GPER-1 in euthymic bipolar patients.","date":"2018","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/29618927","citation_count":11,"is_preprint":false},{"pmid":"27546037","id":"PMC_27546037","title":"Homology Modeling, Validation and Dynamics of the G Protein-coupled Estrogen Receptor 1 (GPER-1).","date":"2016","source":"Molecular informatics","url":"https://pubmed.ncbi.nlm.nih.gov/27546037","citation_count":11,"is_preprint":false},{"pmid":"38992889","id":"PMC_38992889","title":"Activation of GPER1 by G1 prevents PTSD-like behaviors in mice: Illustrating the mechanisms from BDNF/TrkB to mitochondria and synaptic connection.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38992889","citation_count":10,"is_preprint":false},{"pmid":"38217667","id":"PMC_38217667","title":"Activation of GPER-1 Attenuates Traumatic Brain Injury-Induced Neurological Impairments in Mice.","date":"2024","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/38217667","citation_count":10,"is_preprint":false},{"pmid":"29745344","id":"PMC_29745344","title":"Selection of a GPER1 Ligand via Ligand-based Virtual Screening Coupled to Molecular Dynamics Simulations and Its Anti-proliferative Effects on Breast Cancer Cells.","date":"2018","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29745344","citation_count":10,"is_preprint":false},{"pmid":"35569583","id":"PMC_35569583","title":"Bisphenol S induces Agrp expression through GPER1 activation and alters transcription factor expression in immortalized hypothalamic neurons: A mechanism distinct from BPA-induced upregulation.","date":"2022","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35569583","citation_count":10,"is_preprint":false},{"pmid":"29269179","id":"PMC_29269179","title":"Lordosis facilitated by GPER-1 receptor activation involves GnRH-1, progestin and estrogen receptors in estrogen-primed rats.","date":"2018","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/29269179","citation_count":10,"is_preprint":false},{"pmid":"38880044","id":"PMC_38880044","title":"Selenium restored mitophagic flux to alleviate cadmium-induced hepatotoxicity by inhibiting excessive GPER1-mediated mitophagy activation.","date":"2024","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/38880044","citation_count":9,"is_preprint":false},{"pmid":"36096380","id":"PMC_36096380","title":"Overexpression of estrogen receptor GPER1 and G1 treatment reduces SARS-CoV-2 infection in BEAS-2B bronchial cells.","date":"2022","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36096380","citation_count":9,"is_preprint":false},{"pmid":"31790688","id":"PMC_31790688","title":"GPER1 in the thyroid: A systematic review.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31790688","citation_count":9,"is_preprint":false},{"pmid":"26617848","id":"PMC_26617848","title":"Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617848","citation_count":9,"is_preprint":false},{"pmid":"36231664","id":"PMC_36231664","title":"The Interplay of GPER1 with 17β-Aminoestrogens in the Regulation of the Proliferation of Cervical and Breast Cancer Cells: A Pharmacological Approach.","date":"2022","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/36231664","citation_count":9,"is_preprint":false},{"pmid":"31434056","id":"PMC_31434056","title":"Effects of the selective GPER1 agonist G1 on bone growth.","date":"2019","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/31434056","citation_count":9,"is_preprint":false},{"pmid":"33374170","id":"PMC_33374170","title":"GPER1 and microRNA: Two Players in Breast Cancer Progression.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33374170","citation_count":9,"is_preprint":false},{"pmid":"37759449","id":"PMC_37759449","title":"GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37759449","citation_count":9,"is_preprint":false},{"pmid":"36400433","id":"PMC_36400433","title":"Multiplex G Protein-Coupled Receptor Screen Reveals Reliably Acting Agonists and a Gq-Phospholipase C Coupling Mode of GPR30/GPER1.","date":"2022","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36400433","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54295,"output_tokens":9625,"usd":0.15363},"stage2":{"model":"claude-opus-4-6","input_tokens":13676,"output_tokens":3778,"usd":0.244245},"total_usd":0.397875,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"GPER1/GPR30 is a Gs-coupled heptahelical transmembrane receptor that promotes specific binding of estrogens, stimulates adenylyl cyclase, and mediates Gβγ-subunit protein-dependent release of membrane-tethered heparan-bound EGF (HB-EGF), constituting its core non-genomic signaling mechanism.\",\n      \"method\": \"cDNA cloning, pharmacological agonist/antagonist studies, receptor knockdown, adenylyl cyclase assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across multiple labs with multiple orthogonal methods; foundational mechanistic review synthesizing original experimental work\",\n      \"pmids\": [\"22495674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPER1 increases ERK1/2 activity via two Gi/o-mediated mechanisms: a PDZ motif-dependent constitutive mechanism requiring AKAP5 interaction, and a PDZ-independent G-1-stimulated mechanism; the constitutive mechanism requires PI3K but not EGFR transactivation, and involves a protein phosphatase.\",\n      \"method\": \"PDZ motif deletion mutants, AKAP5 knockdown, pertussis toxin, wortmannin, AG1478, FK506, okadaic acid, pharmacological inhibitors in receptor-expressing cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal pharmacological and genetic dissection methods in a single study, rigorous mechanistic controls\",\n      \"pmids\": [\"28450397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In overexpressing HEK293 cells, GPR30/GPER1 couples canonically to Gq-phospholipase C, activating PKC and ERK, and undergoes rapid receptor internalization upon agonist exposure; plasma membrane integration and functional responses are cell-line-dependent.\",\n      \"method\": \"Multiplex GPCR Ca2+ screen, Gq inhibitor YM-254890, PKC and ERK assays, fluorescent fusion protein localization in multiple cell lines\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — unbiased screen plus multiple orthogonal signaling assays, rigorous controls including Gq inhibitor\",\n      \"pmids\": [\"36400433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPER1 constitutively interacts via its C-terminal type I PDZ motif with SAP97 and AKAP5, which anchor the receptor in the plasma membrane and mediate an apparently constitutive, Gi/o-independent decrease in cAMP production.\",\n      \"method\": \"Co-immunoprecipitation, PDZ motif deletion, siRNA knockdown of SAP97 and AKAP5, cAMP assay, pertussis toxin\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding partner identification with functional validation by knockdown and pharmacology\",\n      \"pmids\": [\"28450397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPER1 activates PRKACA (protein kinase A catalytic subunit alpha), which phosphorylates MORC2 at threonine 582; phosphorylated MORC2 has reduced interaction with the CMA components HSPA8 and LAMP2A, protecting it from lysosomal degradation and thereby promoting breast cancer cell proliferation and antiestrogen resistance.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation mutant (T582A), siRNA knockdown, rescue experiments with WT vs. mutant MORC2\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including binding studies, mutagenesis, knockdown, and functional rescue\",\n      \"pmids\": [\"32401166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER1 stimulation by estradiol promotes fibronectin (FN) matrix assembly via release of HB-EGF, recruits integrin α5β1 to fibrillar adhesions, forms integrin α5β1-Shc adaptor protein complexes, enhances focal adhesion and actin stress fiber formation, and enables FN-dependent anchorage-independent growth; mutation of Shc Y317F abolishes these effects.\",\n      \"method\": \"Co-immunoprecipitation, Shc Y317F phosphorylation mutant, haptotaxis assay, hanging drop anchorage-independent growth assay, pharmacological agonist/antagonist\",\n      \"journal\": \"Hormones & cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis of key tyrosine plus multiple functional assays in breast cancer cells\",\n      \"pmids\": [\"25096985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 activation by estradiol or G-1 rapidly induces BDNF release in hippocampal CA3 field, leading to transient Arc protein translation and GluA1-containing AMPA receptor internalization; subsequent mGluR1 activation triggers LTD involving ubiquitination and proteasome-mediated GluA1 degradation.\",\n      \"method\": \"Selective agonist/antagonist pharmacology, BDNF measurement, Arc and GluA1 immunoblotting, proteasome inhibition, LTD electrophysiology\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays (biochemical + electrophysiological) with pharmacological dissection\",\n      \"pmids\": [\"26391661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 activation by estradiol or G-1 stimulates adenylyl cyclase/cAMP production, which activates ERK/MAPK signaling and upregulates Runx2 expression in osteoblasts to promote bone regeneration.\",\n      \"method\": \"cAMP measurement, selective GPER1 antagonist G15 blockade, MAPK inhibitors, Runx2 protein/gene expression, in vivo bone drill-hole model\",\n      \"journal\": \"The Journal of nutritional biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"26345541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER1 agonist G-1 induces vasorelaxation in rat aorta through endothelium-dependent, Src-mediated EGFR transactivation and downstream Akt signaling, independent of ERα/ERβ and PI3K or ERK pathways.\",\n      \"method\": \"Isolated rat aortic ring organ bath pharmacology with selective inhibitors (L-NAME, AG1478, DAPH, Src inhibitor, Akt inhibitor VIII, LY294002, PD98059, G15, MPP, ICI182780)\",\n      \"journal\": \"The Journal of pharmacy and pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — thorough pharmacological dissection with multiple pathway inhibitors, single lab\",\n      \"pmids\": [\"24028616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER1 mediates vasoconstriction in isolated perfused rat kidney via signaling pathways involving ROCK, PKC, p38 MAPK, p42/44 MAPK, tyrosine kinase, EGFR kinase, and voltage-operated Ca2+ channels (VOCCs), but not JNK or PI3K.\",\n      \"method\": \"Isolated perfused rat kidney pharmacology with selective inhibitors (Y-27632, genistein, SB203580, PD98059, GF109203X, SP600125, LY294002, nifedipine, AG-1478, G15), endothelium removal, Western blot for GPER1 expression\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive pharmacological dissection with orthogonal inhibitors, single lab\",\n      \"pmids\": [\"23376418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER1 agonist G-1 regulates vascular smooth muscle cell Ca2+ handling by reducing spontaneous Ca2+ spike activity and blocking L-type voltage-sensitive Ca2+ channel-mediated Ca2+ influx, in a GPER1-dependent manner.\",\n      \"method\": \"Live Ca2+ imaging in A7r5 vascular smooth muscle cells, nifedipine comparison, G15 antagonist blockade, KCl-evoked Ca2+ measurement\",\n      \"journal\": \"Journal of vascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — live cell imaging with pharmacological controls, single lab\",\n      \"pmids\": [\"24080531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER1 mediates estradiol-induced inhibition of aldosterone synthesis through protein kinase A (PKA) signaling; silencing GPER1 lowers aldosterone synthase expression, while G-1 mimics the stimulatory effect of estradiol when ERβ is blocked, and a PKA inhibitor abrogates the G-1 effect.\",\n      \"method\": \"GPER1 siRNA knockdown, ERβ siRNA knockdown, selective agonist G-1, antagonist G-15, PKA inhibitor, aldosterone synthase expression and aldosterone production measurement in HAC15 adrenocortical cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic silencing plus pharmacological dissection, multiple endpoints, single lab\",\n      \"pmids\": [\"25167221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER-1 activation lowers testosterone production by 20-30% in isolated rat Leydig cells and human testicular tissue, via a direct effect on steroidogenesis independent of cell viability.\",\n      \"method\": \"Isolated rat Leydig cells, human testicular tissue, GPER-1 selective agonist G-1, radioimmunoassay for testosterone, ICI 182,780, MTS cell viability assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional pharmacological assay in primary cells and human tissue, single lab\",\n      \"pmids\": [\"24736568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in S and G2/M phases; this effect is GPER1-dependent as confirmed by siRNA knockdown and is independent of ERK/MAPK activity.\",\n      \"method\": \"GPER1 siRNA knockdown, flow cytometry cell-cycle analysis, BrdU DNA synthesis assay, ERK inhibitor PD98059, multiple endothelial cell lines\",\n      \"journal\": \"Journal of vascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor knockdown confirms receptor dependence, pathway inhibitor shows ERK independence, multiple cell lines\",\n      \"pmids\": [\"21273787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 stimulation with GPER1 agonist G1 increased ERK activity in hippocampal slices; the GPER1 antagonist G15 blocked estradiol-mediated enhancement of synaptic transmission; G1 prior application occluded further estradiol-induced synaptic enhancement, and ERK inhibition blocked the response.\",\n      \"method\": \"Extracellular field potential recording in hippocampal slices from WT, ERαKO, and ERβKO mice; selective agonists G1, PPT, DPN; G15 antagonist; ERK inhibitor\",\n      \"journal\": \"Hippocampus\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological occlusion experiments establish GPER1 as primary mediator\",\n      \"pmids\": [\"25980457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Autocrine motility factor (AMF) physically binds to GPER1 and the formed complex translocates from the plasma membrane to the cytoplasm, activating PI3K/AKT signaling to promote endometrial cancer cell growth.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, yeast two-hybrid assay, iTRAQ proteomics, xenograft mouse model\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple binding assays (co-IP, Y2H, IF) with functional in vivo validation, single lab\",\n      \"pmids\": [\"30836961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPER1 activation during pregnancy suppresses type I interferon (IFN) signaling disproportionately in reproductive and fetal tissues; GPER1 inactivation in mice halted fetal development and promoted fetal demise specifically in the context of maternal inflammation.\",\n      \"method\": \"Genetic GPER1 knockout mice, maternal inflammation model, IFN signaling assays, fetal development assessment\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with well-defined physiological phenotype in high-impact journal\",\n      \"pmids\": [\"33446553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GPER1 mediates ubiquitin-proteasome-dependent degradation of ERα by upregulating the Cullin3-based E3 ubiquitin ligase adaptor SPOP; SPOP depletion abrogates GPER1-induced ERα ubiquitination and degradation, and GPER1 activation suppresses ERα-mediated transcription without affecting ERα mRNA.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, SPOP siRNA knockdown, ERα protein/mRNA measurement, selective GPER1 agonist G-1, in vitro and in vivo breast cancer models\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic depletion of downstream effector SPOP plus ubiquitination assay confirms mechanism, multiple endpoints\",\n      \"pmids\": [\"33069770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER1 stimulation alters posttranslational modification of RGSz1, increasing the high-molecular-weight (SUMOylated and glycosylated) RGSz1 isoform localized in detergent-resistant membrane microdomains (DRM), thereby functionally uncoupling 5-HT1AR signaling by sequestering active Gαz.\",\n      \"method\": \"G-1 selective agonist, subcellular fractionation (DRM isolation), Western blot for RGSz1 isoforms, SUMOylation/glycosylation analysis, in vivo oxytocin and ACTH hormone response assays\",\n      \"journal\": \"Neuroendocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical fractionation with PTM characterization plus in vivo functional readout, single lab\",\n      \"pmids\": [\"25402859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPER1 mediates estradiol-induced angiogenesis in HUVECs by upregulating the glycolytic enzyme PFKFB3; GPER1 antagonist G-15 or GPER1 siRNA abolishes the PFKFB3 upregulation, and PFKFB3 inhibition blocks GPER1-mediated HUVEC migration.\",\n      \"method\": \"GPER1 siRNA knockdown, G-15 antagonist, PFKFB3 inhibitor (3PO), selective G-1 agonist, angiogenesis assays (migration, tube formation), PFKFB3 protein expression\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown and pharmacological inhibition confirm pathway, multiple functional assays, single lab\",\n      \"pmids\": [\"28348059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 activation by estradiol or G-1 in ER-negative breast cancer cells (SKBR3, BT-20) activates ERK, AKT, and NF-κB, leading to increased IL-8 secretion; blockade or knockdown of GPER1 inhibits these pathways and attenuates cancer cell migration and invasion, with downstream CXCR1 involvement.\",\n      \"method\": \"GPER1 siRNA knockdown, specific pathway inhibitors, IL-8 ELISA, migration/invasion assays, NF-κB translocation assay\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockdown plus pharmacological pathway dissection, multiple endpoints, single lab\",\n      \"pmids\": [\"23907016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 mediates E2-induced inhibition of ERK1/2 (constitutively activated in granulosa cell tumors) through non-genomic mechanisms, suppressing migration and invasion of metastatic GCT cells; RNA silencing and pharmacological inhibition of GPER1 abrogated this effect.\",\n      \"method\": \"GPER1 siRNA, pharmacological agonist/antagonist, ERK1/2 phosphorylation assay, migration and invasion assays in KGN and COV434 cells\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA silencing plus pharmacology with functional assays, single lab\",\n      \"pmids\": [\"25823895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPER1 activation reduces BBB permeability after global cerebral ischemia by preserving tight junction proteins (occludin and claudin-5) and decreasing VEGF-A expression in hippocampal CA1.\",\n      \"method\": \"Intracerebroventricular G1 agonist injection in ovariectomized rats, IgG extravasation assay, Western blot for occludin, claudin-5, VEGF-A\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with specific protein endpoint measurements, single lab\",\n      \"pmids\": [\"27311857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPER1 mediates estrogen-induced neuroprotection against oxygen-glucose deprivation (OGD) in primary hippocampal neurons via PI3K/Akt-dependent Ask1 inhibition; GPER1 knockdown diminishes and GPER1 overexpression potentiates neuroprotection by membrane-impermeable E2-BSA.\",\n      \"method\": \"GPER1 siRNA knockdown, GPER1 overexpression, E2-BSA (membrane-impermeable estradiol), PI3K/Akt inhibitor LY294002, cell viability assay in primary neurons\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation (KD and overexpression) with pathway inhibitor, single lab\",\n      \"pmids\": [\"27113328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Insulin transactivates the GPER1 promoter and increases GPER1 mRNA and protein expression through a PRKCD/MAPK1/c-Fos/AP1 signaling pathway in leiomyosarcoma cells and cancer-associated fibroblasts; GPER1 upregulation by insulin in turn mediates cell migration through CTGF and potentiates estrogen-stimulated glucose uptake and cell cycle progression.\",\n      \"method\": \"GPER1 promoter-luciferase reporter assay, pharmacological inhibitors, gene-silencing experiments, migration assays, glucose uptake assay\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter assay with inhibitors and silencing, multiple functional endpoints, single lab\",\n      \"pmids\": [\"25012984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 inhibition in breast cancer cells via siRNA knockdown suppresses GPER1-mediated IGFBP-1 induction; 4-OHT activates GPER1, which signals through CREB to induce extracellular IGFBP-1 accumulation, which in turn inhibits IGF-1/Akt signaling.\",\n      \"method\": \"GPER1 siRNA knockdown, conditioned medium transfer assay, IGFBP-1 neutralization, CREB pathway analysis, phospho-Akt measurement\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown plus neutralization of effector with downstream signaling assay, single lab\",\n      \"pmids\": [\"26690777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER1 and ERα36 (36 kDa splice variant) physically interact, and in human monocytes, ligand-activated ERα36 directly interacts with NF-κB p65 subunit in the nucleus to inhibit LPS-induced IL-6; GPER1 acts as a co-regulator in this process as its inhibition blocks the estrogen effect on IL-6.\",\n      \"method\": \"Co-immunoprecipitation, GPER1 selective inhibitor, siRNA knockdown, NF-κB reporter assay, IL-6 ELISA in human primary monocytes\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP for physical interaction, functional knockdown, single lab\",\n      \"pmids\": [\"26394816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In breast cancer cells, ERα36 and GPER1 physically interact (especially after LPS treatment), and GPER1 directly interacts with NF-κB; together ERα36 and GPER1 inhibit TLR4/NF-κB-mediated inflammation independently of ERα66.\",\n      \"method\": \"Co-immunoprecipitation, ERα36 overexpression, siRNA knockdown of ERα36 and GPER1, NF-κB reporter assay, cytokine (TNFα, IL-6) measurement\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple co-IP experiments confirming physical interactions with functional validation, single lab\",\n      \"pmids\": [\"34299224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GPER1 deletion in salt-sensitive hypertensive rats by CRISPR/Cas9 reduced blood pressure and was associated with altered gut microbiota and short-chain fatty acids; microbiotal transplantation from Gper1+/+ hypertensive rats reversed the cardiovascular protection of Gper1 deletion, demonstrating that GPER1 promotes microbiota alterations contributing to cardiovascular pathology.\",\n      \"method\": \"Multiplexed guide RNA CRISPR/Cas9 genomic excision of Gper1, fecal microbiota transplantation, blood pressure measurement, vascular relaxation assay, short-chain fatty acid measurement\",\n      \"journal\": \"Hypertension (Dallas, Tex. : 1979)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — complete gene ablation with microbiota transplantation rescue experiment, multiple endpoints\",\n      \"pmids\": [\"30354811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER1 and CerS4/CerS5 promoter activation by 17β-estradiol is mediated through AP-1 (c-Jun/c-Fos dimerization); promoter deletion and mutation constructs demonstrated this AP-1 dependence, and GPER1 co-transfection modulated ceramide synthase promoter activities.\",\n      \"method\": \"Luciferase reporter assay with promoter deletion and mutation constructs, GPER1 co-transfection, fulvestrant inhibition, MCF-7 and MDA-MB-231 cells\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis identifying functional AP-1 elements with GPER1 co-expression, single lab\",\n      \"pmids\": [\"25451689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPER1 overexpression in MCF-7 breast cancer cells causes G1 cell cycle arrest, induces autophagy/mitophagy, reduces basal respiration and glycolysis; stable GPER1 overexpression reduces CerS4, CerS5, and CerS6 promoter activity with the CerS5 effect mediated by GSK-3β signaling.\",\n      \"method\": \"Stable GPER1 overexpression, cell cycle analysis, autophagy assays, Seahorse metabolic assay, luciferase promoter assay, GSK-3β signaling inhibition\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — overexpression model with multiple metabolic readouts and promoter assay, single lab\",\n      \"pmids\": [\"31082617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In mucopolysaccharidosis (MPS) I cells, GPER1 forms anomalous aggregates that co-localize with glycosaminoglycans (GAGs); enzyme replacement therapy that degrades GAGs causes disappearance of the GPER1 aggregates, indicating that GAG accumulation drives GPER1 aggregation rather than altered protein expression.\",\n      \"method\": \"Transcriptomic analysis, immunofluorescence localization, enzyme replacement treatment, correlation with GAG levels in MPS I and MPS II patient-derived cells\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization plus GAG degradation rescue experiment, single lab\",\n      \"pmids\": [\"35537249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In embryonic hippocampal mHippoE-18 cells, endogenous GPER1 mediates 17β-estradiol-induced potentiation of forskolin-stimulated cAMP; however, GPER1-selective antagonists G15 and G36 paradoxically switch this to an inhibitory response, and aldosterone mimics the inhibitory coupling even without antagonists, demonstrating biased agonism/antagonism dependent on ligand identity.\",\n      \"method\": \"cAMP assay with selective GPER1 agonists (G1, tamoxifen, ICI182780) and antagonists (G15, G36), ERα/ERβ agonists (PPT, DPN) in an endogenously expressing hippocampal cell line\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — endogenously expressing cell line avoids overexpression artifacts; multiple ligand comparisons demonstrating biased coupling, single lab\",\n      \"pmids\": [\"26998610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GPER1 knockdown in gastric cancer cells suppresses proliferation, migration, and invasion by inhibiting PI3K/AKT-mediated EMT; PI3K activator 740Y-P reverses the effects of GPER1 knockdown on EMT markers, placing GPER1 upstream of PI3K/AKT in this pathway.\",\n      \"method\": \"GPER1 siRNA knockdown, GPER1 overexpression, PI3K activator rescue, EMT marker Western blot, proliferation/migration/invasion assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation plus pathway rescue experiment, single lab\",\n      \"pmids\": [\"33425895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BPS (bisphenol S) induces Agrp mRNA expression in hypothalamic neurons through GPER1 signaling; GPER1 antagonist G15 prevents BPS-mediated Agrp upregulation independently of Atf3 and Klf4 induction.\",\n      \"method\": \"G15 pharmacological antagonism, BPS treatment of immortalized hypothalamic cell lines, RT-PCR for Agrp and multiple transcription factors\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological pathway dissection without receptor knockdown, single lab\",\n      \"pmids\": [\"35569583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPER1 activation by G-1 in macrophages reduces M1 and M2 macrophage polarization, downregulates immune pathway activation and inactivates MAPK pathways, thereby reducing tubular epithelial cell injury and fibroblast ECM production in co-culture; GPER1 deletion in male UUO mice accelerates renal fibrosis.\",\n      \"method\": \"GPER1 agonist G-1 in OVX and male UUO mouse models, Gper1 knockout mice, RNA-sequencing, immunoblotting for MAPK pathway, macrophage polarization assays, co-culture experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological activation with RNA-seq and functional co-culture assays, single lab\",\n      \"pmids\": [\"38086848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPER1 activation by G-1 in multiple myeloma cells triggers apoptosis and upregulates the miR-29b oncosuppressive network by blunting a miR-29b-Sp1 feedback loop; this reduces MM growth in xenograft models even in bortezomib-resistant cells.\",\n      \"method\": \"Selective GPER1 agonist G-1, miR-29b expression analysis, Sp1 pathway assessment, apoptosis assay, xenograft mouse models\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway identified with in vivo validation, single lab\",\n      \"pmids\": [\"37759449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"E2 enhances melatonin synthesis (AANAT expression) in human trophoblast cells through GPER1-PKA-CREB signaling pathway; pharmacological dissection established this specific receptor-signaling axis in placental hormone homeostasis.\",\n      \"method\": \"Primary human trophoblast cell culture, GPER1 agonist/antagonist pharmacology, PKA inhibitor, CREB pathway analysis, AANAT expression measurement\",\n      \"journal\": \"Journal of pineal research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with multiple inhibitors in primary human trophoblast cells, single lab\",\n      \"pmids\": [\"37746893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER1 mediates ROCK-2 upregulation in rat coronary vascular endothelial cells via EGFR transactivation and Gi/o protein signaling, as evidenced by inhibition with pertussis toxin (PTX), AG-1478, G-15 antagonist, and actinomycin-D; ERα and ERβ selective agonists had no effect on ROCK-2.\",\n      \"method\": \"Western blot for ROCK-2 and GPER1, pertussis toxin, AG-1478, G-15 antagonist, actinomycin-D, primary rat coronary vascular endothelial cells\",\n      \"journal\": \"Endocrine regulations\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological approach in primary cells, no genetic validation, single lab\",\n      \"pmids\": [\"23641788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPER1 activation by G-1 protects retinal ganglion cells from NMDA-induced apoptosis via PI3K/Akt pathway; pharmacological PI3K/Akt inhibitor LY294002 counteracts G-1 protection, and antibody array shows decreased Bad, Caspase 3, Caspase 7, Smad2, P53, and TAK1 in G-1-treated retinae.\",\n      \"method\": \"NMDA and AOH mouse models, G-1 agonist, G-15 antagonist, tamoxifen (ERα/ERβ blocker), LY294002 (PI3K inhibitor), immunofluorescence, TUNEL, antibody array\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor specificity established by G15 vs. tamoxifen pharmacology plus pathway inhibitor, single lab\",\n      \"pmids\": [\"31586450\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GPER1 (GPR30) is a seven-transmembrane G protein-coupled receptor that functions as a membrane estrogen receptor, binding 17β-estradiol to activate multiple intracellular signaling cascades: it couples to Gs to stimulate adenylyl cyclase/cAMP, to Gi/o to activate ERK1/2 (via a PDZ motif/AKAP5-dependent constitutive mechanism and a ligand-stimulated PDZ-independent mechanism), and in some cell contexts to Gq-phospholipase C; it also transactivates EGFR via Gβγ-dependent release of membrane-tethered HB-EGF, activates PI3K/Akt, ROCK, PKC, and MAPK pathways, regulates fibronectin matrix assembly through integrin α5β1-Shc complexes, and mediates non-genomic control of cellular functions including BDNF release, calcium handling, PFKFB3-dependent angiogenesis, ERα ubiquitin-proteasome degradation via SPOP/Cullin3, MORC2 stabilization via PRKACA phosphorylation, IFN signaling suppression during pregnancy, and serotonin receptor desensitization through RGSz1 posttranslational modification, with its subcellular localization (plasma membrane vs. endomembrane compartments) being cell-type-dependent and influencing downstream signaling outputs.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GPER1 (GPR30) is a seven-transmembrane G protein-coupled receptor that functions as a membrane estrogen receptor, mediating rapid non-genomic responses to 17β-estradiol and synthetic ligands across diverse tissues including breast, brain, vasculature, and reproductive organs. It couples to multiple G protein families—Gs to stimulate adenylyl cyclase/cAMP, Gi/o to activate ERK1/2 via both constitutive PDZ/AKAP5-dependent and ligand-stimulated mechanisms, and Gq to engage phospholipase C/PKC—and transactivates EGFR through Gβγ-dependent release of membrane-tethered HB-EGF, converging on PI3K/Akt, MAPK, PKA/CREB, and NF-κB signaling cascades [PMID:22495674, PMID:28450397, PMID:36400433]. These signaling outputs mediate cell-type-specific functions including BDNF-dependent synaptic plasticity and AMPA receptor internalization in hippocampus, fibronectin matrix assembly via integrin α5β1-Shc complexes, PFKFB3-dependent angiogenesis, SPOP/Cullin3-mediated ERα proteasomal degradation, steroidogenesis regulation, and calcium channel modulation in vascular smooth muscle [PMID:26391661, PMID:25096985, PMID:28348059, PMID:33069770, PMID:24080531]. GPER1 activation during pregnancy suppresses type I interferon signaling in reproductive and fetal tissues, and genetic loss of GPER1 in mice causes fetal demise during maternal inflammation [PMID:33446553].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Establishing that GPER1 is a bona fide Gs-coupled receptor for estrogen resolved the question of whether non-genomic estrogen signaling operates through a dedicated GPCR rather than through nuclear ERs alone, defining its core mechanism as adenylyl cyclase stimulation and Gβγ-dependent HB-EGF release for EGFR transactivation.\",\n      \"evidence\": \"Convergent pharmacological, knockdown, and adenylyl cyclase assay studies synthesized from multiple labs\",\n      \"pmids\": [\"22495674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of estrogen binding to a GPCR fold not resolved\", \"Relative contribution of Gs vs. other G proteins in native tissues unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defining GPER1's vascular signaling repertoire revealed that the same receptor drives opposing vascular responses—vasorelaxation via Src/EGFR/Akt in aorta and vasoconstriction via ROCK/PKC/MAPK/VOCCs in kidney—establishing GPER1 as a context-dependent modulator of vascular tone and calcium handling.\",\n      \"evidence\": \"Pharmacological dissection with extensive inhibitor panels in isolated rat aortic rings, perfused kidney, and vascular smooth muscle Ca²⁺ imaging\",\n      \"pmids\": [\"24028616\", \"23376418\", \"24080531\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular determinants of tissue-specific G protein coupling not identified\", \"No genetic validation of receptor dependence in vascular models\", \"Endogenous ligand concentrations in vascular beds not measured\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstration that GPER1 stimulation promotes fibronectin matrix assembly through HB-EGF/integrin α5β1/Shc signaling—with Shc Y317F phosphorylation mutant abolishing anchorage-independent growth—established GPER1 as a direct link between estrogen signaling and extracellular matrix remodeling in breast cancer.\",\n      \"evidence\": \"Co-immunoprecipitation, Shc Y317F mutant, haptotaxis, and anchorage-independent growth assays in breast cancer cells\",\n      \"pmids\": [\"25096985\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether integrin α5β1-Shc axis operates in non-cancer epithelial cells unknown\", \"Direct Shc binding site on GPER1 signaling complex not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of GPER1's role in modulating serotonin receptor desensitization through posttranslational modification of RGSz1 and sequestration of Gαz in detergent-resistant membrane microdomains provided a molecular mechanism for estrogen-serotonin crosstalk relevant to neuroendocrine regulation.\",\n      \"evidence\": \"Subcellular fractionation, RGSz1 SUMOylation/glycosylation analysis, and in vivo oxytocin/ACTH response after G-1 administration\",\n      \"pmids\": [\"25402859\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between GPER1 and RGSz1 not demonstrated\", \"Enzymatic machinery mediating RGSz1 SUMOylation downstream of GPER1 not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that GPER1 mediates estradiol's effects on steroid hormone production—inhibiting aldosterone synthesis via PKA signaling and reducing testosterone in Leydig cells—expanded the receptor's role beyond classical signal transduction to endocrine homeostasis.\",\n      \"evidence\": \"GPER1 siRNA, selective agonist G-1, PKA inhibitor in HAC15 adrenocortical cells; G-1 treatment of isolated rat Leydig cells and human testicular tissue\",\n      \"pmids\": [\"25167221\", \"24736568\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Steroidogenic enzyme targets directly regulated by GPER1-PKA axis not fully mapped\", \"Physiological relevance under normal endogenous estrogen levels not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that GPER1 activation in hippocampus triggers BDNF release, transient Arc translation, GluA1 AMPA receptor internalization and subsequent proteasomal degradation established a complete molecular cascade through which estrogen rapidly modulates synaptic plasticity.\",\n      \"evidence\": \"Pharmacological dissection combined with electrophysiological LTD recording and biochemical measurement of Arc, GluA1, and BDNF in hippocampal slices\",\n      \"pmids\": [\"26391661\", \"25980457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPER1 acts cell-autonomously in neurons vs. through glia not resolved\", \"Structural mechanism of GPER1-BDNF release coupling unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Dissection of two distinct ERK1/2 activation modes—a constitutive PDZ/AKAP5/Gi/o-dependent pathway requiring PI3K and a ligand-stimulated PDZ-independent pathway—resolved how GPER1 maintains basal signaling tone while retaining stimulus-responsiveness, and identified SAP97 and AKAP5 as scaffold partners anchoring GPER1 at the plasma membrane.\",\n      \"evidence\": \"PDZ motif deletion mutants, AKAP5/SAP97 knockdown, pertussis toxin, pathway inhibitors in receptor-expressing cells\",\n      \"pmids\": [\"28450397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal or cryo-EM structure of GPER1-AKAP5 complex not available\", \"Whether PDZ-dependent constitutive signaling occurs in all GPER1-expressing cell types unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of PFKFB3 as the downstream effector through which GPER1 drives endothelial angiogenesis linked GPER1 signaling to glycolytic metabolic reprogramming in vascular biology.\",\n      \"evidence\": \"GPER1 siRNA and G-15 antagonist abolish PFKFB3 upregulation; PFKFB3 inhibitor blocks GPER1-mediated HUVEC migration and tube formation\",\n      \"pmids\": [\"28348059\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factor(s) mediating GPER1-dependent PFKFB3 upregulation not identified\", \"In vivo angiogenesis validation in GPER1 knockout mice not performed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that GPER1 activates PRKACA to phosphorylate MORC2-T582, protecting it from chaperone-mediated autophagy and promoting antiestrogen resistance, revealed a direct mechanism linking GPER1 to chromatin regulator stability and therapy resistance in breast cancer.\",\n      \"evidence\": \"Co-immunoprecipitation, T582A phospho-mutant, siRNA knockdown, rescue with WT vs. mutant MORC2\",\n      \"pmids\": [\"32401166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MORC2 stabilization is a general GPER1 output or breast cancer-specific unknown\", \"Upstream mechanism selecting MORC2 as PRKACA substrate in GPER1 context not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Establishing that GPER1 promotes ERα degradation through upregulation of the SPOP/Cullin3 E3 ubiquitin ligase adaptor provided a molecular mechanism for the functional antagonism between GPER1 and classical nuclear estrogen receptor signaling.\",\n      \"evidence\": \"SPOP siRNA abrogates GPER1-induced ERα ubiquitination and degradation; GPER1 agonist G-1 suppresses ERα-mediated transcription without affecting ERα mRNA\",\n      \"pmids\": [\"33069770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPER1 directly regulates SPOP transcription or protein stability not distinguished\", \"In vivo tissue-specific impact on ERα levels in GPER1 knockout not assessed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Genetic knockout studies established that GPER1 suppresses type I interferon signaling in reproductive and fetal tissues during pregnancy, and that loss of GPER1 leads to fetal demise during maternal inflammation—demonstrating an essential physiological role beyond cancer biology.\",\n      \"evidence\": \"GPER1 knockout mice, maternal inflammation model, IFN signaling assays, fetal development assessment\",\n      \"pmids\": [\"33446553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which GPER1 suppresses IFN signaling not defined\", \"Cell types responsible for IFN suppression in reproductive tract not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating canonical Gq-PLC coupling and rapid agonist-induced internalization in an unbiased multiplex screen, with cell-line-dependent plasma membrane integration, clarified that GPER1's G protein selectivity and subcellular localization are not fixed properties but vary by cellular context.\",\n      \"evidence\": \"Multiplex GPCR Ca²⁺ screen, Gq inhibitor YM-254890, PKC/ERK assays, fluorescent fusion protein localization across multiple cell lines\",\n      \"pmids\": [\"36400433\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of cell-type-specific G protein coupling preference not identified\", \"Structural basis for Gq vs. Gs vs. Gi/o selectivity unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Expansion of GPER1's immunomodulatory role to macrophage polarization and renal fibrosis—where GPER1 activation suppresses M1/M2 polarization via MAPK inactivation and GPER1 deletion accelerates fibrosis—extended the receptor's physiological relevance to tissue repair and inflammation beyond pregnancy.\",\n      \"evidence\": \"GPER1 agonist and knockout mice in UUO renal fibrosis model, RNA-seq, macrophage polarization and co-culture assays\",\n      \"pmids\": [\"38086848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GPER1 signaling targets in macrophages upstream of MAPK inactivation not mapped\", \"Whether anti-fibrotic effect is macrophage-autonomous or involves other cell types not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for GPER1's estrogen binding within a GPCR fold, the molecular determinants governing cell-type-specific G protein coupling selectivity, and the relative physiological contributions of constitutive versus ligand-stimulated signaling in vivo remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of GPER1 with or without ligand\", \"In vivo contribution of constitutive PDZ/AKAP5-mediated signaling to physiology unknown\", \"Mechanism of biased agonism at GPER1 (e.g., aldosterone vs. estradiol) not structurally or biochemically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 32]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 18, 26, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 3, 15]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 15, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 7, 8, 9, 23, 33]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [16, 26, 27, 35]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 17]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [6, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [36, 39]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"AKAP5\",\n      \"SAP97\",\n      \"SPOP\",\n      \"MORC2\",\n      \"ESR1\",\n      \"AMF\",\n      \"RELA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}